The Northstar AI Results Explorer can be incorporated directly into existing clinical workflows. Within the platform, radiologists can not only view AI-produced images and reports, but also assess individual measurements, markings and other findings generated by the technology, examining the AI’s decision-making process to determine and fine-tune the data’s accuracy and thus accept or reject the algorithm’s findings.
The FDA gave the platform a “first-of-kind” determination, labeling it a Class I medical device and therefore granting it full commercial availability.
Editor’s note: This article was updated June 25 at 9:00 a.m. to clarify the FDA’s determination.
More articles about AI:
Updated White House AI policy prioritizes public-private collaboration
Philips updates AI-enabled cardiac ultrasound platform to make it faster, easier to use
AI-guided robotic device replaces endoscopy in diagnosing colon cancer
